0 Comentários
0 Compartilhamentos
840 Visualizações
0 Anterior
Pesquisar
Conheça novas pessoas, crie conexões e faça novos amigos
-
Faça Login para curtir, compartilhar e comentar!
-
MEK Inhibitors Market: How Is Neurofibromatosis Type 1 Approval Creating a New Rare-Disease Revenue Stream?MEK inhibitors targeting neurofibromatosis type 1-associated plexiform neurofibromas — the oral allosteric MEK1/2 inhibitors selumetinib (Koselugo, AstraZeneca) and mirdametinib (Gomekli, SpringWorks Therapeutics) approved for pediatric and adult NF1 patients with symptomatic, inoperable tumors — represent the fastest-growing indication segment in the MEK inhibitor market, with the...0 Comentários 0 Compartilhamentos 1K Visualizações 0 Anterior
-
Neurofibromatosis Type 1 Market – Advancing Targeted Therapies for Genetic Tumor DisordersMarket Overview The neurofibromatosis type 1 market is evolving as pharmaceutical innovation delivers targeted therapeutic options for this genetic disorder characterized by nervous system tumor growth. Recent advances in MEK inhibitor therapies and growing diagnostic awareness are reshaping treatment approaches for patients affected by this condition, which previously had limited...0 Comentários 0 Compartilhamentos 132 Visualizações 0 Anterior